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BEHÇET’S disease (BD) is a current systemic vasculitis
of  unknown  aetiology.  Eyes,  skin,  joints,  the  oral
cavity, genital system, blood vessels, central nervous
system  and  lung  are  usually  involved.  Defective
regulation of programmed cell death (apoptosis) may
play a role in the development of (BD), and the proto-
oncogene Bcl-2 is involved in the control of apoptosis
in immunocompetent cells. We therefore wished to
investigate the expression of Bcl-2 in the peripheral
lymphocytes  and  in  two  inflammatory  sites  of
patients with active BD: bronchoalveolar lavage (BAL)
and cerebrospinal fluid (CSF) lymphocytes. Levels of
Bcl-2 expression in the lymphocytes of patients with
BD  and,  for  comparison,  in  the  lymphocytes  of
healthy controls and non-inflammatory neurological
diseases  (NIND),  were  studied  by  two-colour  cyto-
fluorography  and  RNA  analysis.  In  BD  patients,  a
significant proportion of T cells expressed increased
amounts of Bcl-2  protein, both in peripheral blood
and  in  inflammatory  sites.  Mononuclear  cells  of
patients with BD showed increased amount of Bcl-2
messenger RNA. The in vitro incubation of T lympho-
cytes  with  IL-10,  significantly  increased  the  Bcl-2
expression,  specifically  in  T  lymphocytes  from
inflammatory sites. In active BD, stimulation of HSV-1
T  lymphocytes  slightly  increased  Bcl-2  expression,
not significantly different from unstimulated HSV-1 T
cells.  The  occurrence  of  circulating  T  lymphocytes
with abnormally high Bcl-2 expression in peripheral
circulation  and  in  inflammatory  sites  may  be
explained in part by the increased in vivo activation
levels, and by aetiopathological agent(s): our findings
seem  to  indicate  an  important  role in  the chronic
inflammation in BD.
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Introduction
Behçet’s disease (BD) is a polysymptomatic, recurrent
systemic  vasculitis  with  a  chronic  course  and  an
unknown aetiology.1 Several organs or systems can be
involved and the resultant symptomatology and sever-
ity depend on the system affected.1 The main clinical
features  are:  oral  aphthous,  genital  ulcers,  ocular
lesions, skin lesions, arthritis, central nervous system
manifestations,  vasculitis1 and  other  less  frequent
findings, such as pulmonary manifestations.2 Increas-
ing evidence indicates that immunological processes
and  a  variety  of  cytokines  may  contribute  to  the
pathophysiological process in BD.3 We have recently
reported that patients with BD have a dysregulation in
programmed cell death.4,5
Programmed cell death (apoptosis) is important in
down-modulation of immune responses after activa-
tion  and  proliferation  of  inflammatory  cells.  It  has
been suggested  that dysregulated  apoptosis of  lym-
phocytes  may  be  linked  to  the  development  of
autoimmune diseases: Sj¨ ogren’s syndrome,6 systemic
lupus erythematosus (SLE)7 and rheumatoid arthritis
(RA).8
Bcl-2 is a proto-oncogene that regulates apoptosis
of  several  cell  types.  Bcl-2  plays  a  role  in  the
maintenance of the immune  system, since inactiva-
tion of Bcl-2 in mice leads to the disappearance of the
lymphoid  system.9 Lymphocyte  activation  in  active
BD  was  increased,  in  particular  in  the  inflam-
matory  sites,1 so  it  is  possible  that  the  expression
of  apoptosis-regulating  proteins,  like  Bcl-2,  is
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studied Bcl-2 expression in inflammatory sites: bron-
choalveolar lavage and cerebrospinal fluid.
Patients and Methods
Patients
BD was determined according to the criteria of the
International  Group  for  Behçet’s  disease.10 BD
patients were receiving treatment including steroids
and  colchicine.  Characteristics  of  BD  patients  are
shown in Table 1. Different patient groups were used
for  flow  cytometry  and  nucleic  acid  hybridization
studies.
Bronchoalveolar  lavage  was  isolated  from  10
patients  with  active  BD  with  lung  involvement
(chronic cough associated to interstitial shadows on
chest X-ray or pulmonary aneurysms).11 Cerebrospi-
nal fluid lymphocytes were isolated from five patients
with neurological manifestations.4
As  controls  we  studied  peripheral  blood  mono-
nuclear cells (PBMC) and  cerebrospinal  fluid  (CSF)
lymphocytes from 10 patients with non-inflammatory
neurological diseases (NIND) and the bronchoalveo-
lar  lavage  cells  (BAL)  from  12  persons  undergoing
routine  investigations  for  bronchial  carcinoma  and
whose lung X-rays were normal.
Reagents
Anti-human  bcl-2  (isotype  IgG)  monoclonal  anti-
bodies  (mAb)  were  purchased  from  Dako.  Anti-
CD3mAb OKT3 was from Becton-Dickinson (Moun-
tain View,  CA, USA). The negative control antibody
11G2 was mouse IgG1 mAb to chicken Bu-1b alloanti-
gen.12 Fluorescein  isothiocyanate (FITC)-conjugated
anti-human  CD3,  and  mouse  IgG  were  purchased
from  Becton-Dickinson.  Unspecific  mouse  IgG
(I-5381)  was  purchased from  Sigma  (St  Louis,  MO,
USA) and streptavidin–phycoerythrin (PE) (7100–09)
from  Southern  Biotechnology  Associates  (Birming-
ham, AL, USA). Purified human recombinant IL-2, IL-
10,  and neutralizing anti-IL-10mAb were from Gen-
zyme Diagnotics.
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Table 1. Clinical features of patients with Behçet’s disease
Patient Age/sex Disease activity Symptoms at the time of sampling
1 40/M Active Or ulcer – Gen ulcer – Uveitis – Pulm.
2 45/M Remission No symptom
3 36/F Active Or ulcer – Gen ulcer – Uveitis – EN
4 37/F Active Or ulcer – Gen ulcer – Uveitis
5 28/M Active Or ulcer – Gen ulcer
6 57/M Active Or ulcer – Gen ulcer – Pulm
7 26/M Active Or ulcer – Gen ulcer – Uveitis – Pulm
8 45/M Active Or ulcer – Gen ulcer – Arthritis
9 47/M Active Or ulcer – Gen ulcer – Uveitis – CNS – Arthritis
10 63/M Partial remission Or ulcer
11 29/F Remission No symptom
12 32/M Active Or ulcer – Gen ulcer – Uveitis – Arthritis
13 35/M Active Or ulcer – Gen ulcer – CNS
14 56/M Active Or ulcer – Gen ulcer – Uveitis
15 58/M Active Or ulcer – Gen ulcer – Arthritis
16 33/M Active Or ulcer – Gen ulcer – Uveitis
17 34/M Active Or ulcer – Gen ulcer – Uveitis – Pulm
18 21/M Active Or ulcer – Gen ulcer – EN
19 18/M Active Or ulcer – Gen ulcer – Arthritis
20 40/M Active Or ulcer – Gen ulcer – Uveitis
21 49/F Active Or ulcer – Gen ulcer
22 42/M Active Or ulcer – Gen ulcer – Uveitis – EN
23 35/M Partial remission Or ulcer – Gen ulcer – Arthritis
24 27/M Active Or ulcer – Gen ulcer – Uveitis – Arthritis
25 29/M Active Or ulcer – Gen ulcer – Uveitis – Pulm
26 28/M Active Or ulcer – Gen ulcer – Uveitis – CNS
27 17/M Active Gen ulcer – Uveitis – Arthritis
28 36/F Active Or ulcer – Gen ulcer – EN
29 34/M Active Or ulcer – Gen ulcer – Uveitis – Pulm
30 52/M Active Or ulcer – Gen ulcer – Uveitis – Pulm
31 46/M Active Or ulcer – Gen ulcer – Uveitis – CNS
32 43/M Active Or ulcer – Gen ulcer – Uveitis – CNS
33 27/M Active Or ulcer – Gen ulcer – Uveitis – Pulm
34 36/M Active Or ulcer – Gen ulcer – Uveitis – Arthritis – Pulm
35 38/M Active Or ulcer – Uveitis – Arthritis – Pulm
Or ulcer, oral aphthous  ulceration; Gen ulcer, genital ulceration;  EN, erythema nodosum;  CNS, central nervous system involvement; Pulm,
pulmonary manifestation, artery aneurysm.Cell preparations and cultures
Peripheral blood, cerebrospinal and bronchoalveolar
lymphocytes were isolated by Ficoll-Hypaque (Phar-
macia, Uppsala, Sweden) density-gradient centrifuga-
tion and washed twice with PBS at +4°C. Lympho-
cytes were cultured at l06 cells/ml per well in Iscove’s
modified Dulbecco’s medium (Gibco) supplemented
with 10% fetal calf serum and 50m g/ml gentamycin.
Cells were cultured  in  24-well  plates (Costar,  Cam-
bridge, MA) at 37°C in a 5% CO2 incubator (Jouan). IL-
2  (50U/ml),  IL-10  (100U/ml)  or  anti-IL-10mAbs
(2m g/ml)  were added at the onset of  the cultures.
After a culture period of 7 days, cells were harvested
and  washed  twice  with  1%  bovine  serum  albumin
(BSA).  Cells  were  stained  and  analysed  using  flow
cytometry as described below.
Generation of HSV-1 stimulated T cells
Four  millilitres  of  cells  at  2  3 106 cells/ml  were
cultured in tissue culture flasks, in the presence of
UV-inactivated HSV-1, in an incubator with 5% CO2
and 95% air for 6 days, as previously reported.13 On
the  day  of  testing,  the  cells  were  washed and  the
number of viable cells was determined by trypan blue
exclusion. The cells were resuspended in RPMI 1640
medium supplemented with 25mM Hepes buffer and
10% heat-inactivated FCS.
Immunofluorescence staining and flow
cytometric analysis
A total of 106 cells were incubated for 30min with
anti-Bcl-2 monoclonal antibody (mAbs), followed by
incubations  with  biotinylated  anti-mouse  IgG  and
streptavidin–PE in 1% BSA, 0.3% saponin, followed by
two washes in 1% BSA, 0.1% saponin. For two-colour
analysis, cells were then incubated with unspecific
mouse  IgG  for  15min  and  stained  with  FITC-con-
jugatedmAbs for 30min  without saponin. The  neg-
ative controls included the replacement of anti-Bcl-
2mAb with a negative control antibody (11G2) of the
same isotype and the staining of cells without saponin
permeabilization.  Cells  with  light  scatter  character-
istics of lymphocytes were gated and analysed using
LYSYS II software from a FACScan (Becton-Dickinson)
flow cytometer.
RNA isolation and nucleic acid hybridization
Total RNA was extracted from PBMC and inflamma-
tory sites cells (BAL and CSF mononuclear cells) as
described  by  Chirgwin  et  al.14 Briefly,  cells  were
homogenized  in  4M  guanidium  isothiocyanate and
RNAs were purified with ultracentrifugation through
caesium chloride cushions. To verify the integrity of
RNA preparations, a small amount of RNA from each
sample was electrophoresed in 1% agarose/formalde-
hyde and stained with ethidium bromide. Five micro-
grams  of  total  RNA  were  dot blotted  onto a nylon
membrane  (Hybond-N+;  Amersham  International).
The filter was hybridized and washed under stringent
conditions according to the manufacturer’s protocol.
Human  Bcl-2  cDNA  was  excised  from  pN2-H-BCL2
vector.15 It  recognizes  the  appropriate  size  8.5-kb
RNA. The glyceraldehyde 3-phosphate dehydrogenase
cDNA  clone  pHGAPDH  was  used  as  a  reference
probe.16 The  probes  were  labelled  with  [32P]dATP
(PB.10204; Amersham), using a random priming DNA
labelling  kit  (70200;  USB,  Cleveland, OH,  USA),  to
obtain specific activities of 1 – 2 3 109 dpm/m g. After
labelling,  probes  were  run  through  Sephadex  G50
spin columns. The autoradiograms from the sequen-
tial hybridization of a dot blot filter with Bcl-2 and
GAPDH  probes  were  analysed  with  a  scanning
densitometer,  and  the  densitometric  readings  were
normalized to the amount of RNA in each sample.
Results
Bcl-2 immunofluorescence
To quantitate the expression of Bcl-2 protein in the T
lymphocytes from patients with active BD, we studied
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Table 2. Bcl-2 expression as mean fluorescence intensity (MFI) in peripheral blood T lymphocytes (PBMC), bronchoalveolar
lavage  T  lymphocytes  (BAL)  and  cerebrospinal  fluid  lymphocytes  (CSF)  from  controls  and  active  BD  with  pulmonary
manifestations and neurological involvement
Sample No. of
patients
Mean fluorescence
intensity ± S.D.
Bcl-2-positive lymphocytes ± SD (%)
Medium +IL-2 +IL-10
Control PBL 25 56 ± 17 72 ± 6 84 ± 22* 96 ± 12*
Active BD-PBL 35 92 ± 8† 87 ± 8 90 ± 15 87 ± 8
Control BAL 12 28 ± 14 52 ± 6 80 ± 3* 74 ± 10*
Active BD-BAL 10 46 ± 10† 78 ± 3 74 ± 10 90 ± 7*
NIND-CSF 10 32 ± 14 53 ± 7 72 ± 6* 70 ± 3*
Active BD-CSF 05 63 ± 6† 74 ± 5* 94 ± 4* 96 ± 15*
Percentage (%) of Bcl-2 expression was tested after IL-2 and IL-10 stimulation.
*P<0.001, percent of Bcl-2 expression in active BD after IL-2 and IL-10 incubation compared to the control incubated with medium alone.
†P<0.001, MFI expression in active BD compared to the respective control sites.200
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Bcl-2 expression in 35 peripheral blood mononuclear
cells (PBMC), 10 BAL and five CSF from patients with
active BD, using flow cytometry. As shown in Table 2,
Bcl-2  expression  in  PBL  from  active  BD  was  high
compared to healthy controls. In every lymphocyte
sample, from CSF and BAL of active BD >80% were
Bcl-2 positive when compared to CSF from NIND and
BAL from healthy controls. In addition, the MFI of Bcl-
2-positive cells in the BAL and CSF from active BD
were  clearly  increased  when  compared  to  BAL  of
healthy controls and CSF  from  patients with NIND
(Figs 1 and 2).
Effect of IL-2 and IL-10 on Bcl-2 expression
The Bcl-2 expression analysed by flow cytometry was
studied in cultured T cells incubated with IL-2 and IL-
10. The addition of IL-2 did not change significantly the
percentage of Bcl-2 expression on peripheral T cells
and T  lymphocytes  from  inflammatory  sites:  bron-
choalveolar lavage  and  cerebrospinal  fluid  lympho-
cytes. However, IL-10 increased significantly the Bcl-2
expression  (Table  2),  specifically  in T  lymphocytes
from inflammatory sites. The increased Bcl-2 expres-
sion was abrogated when anti-IL10 was added.
K. Hamzaoui et al.
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FIG. 1. Immunofluorescence histogram showing Bcl-2 expression lymphocytes of bronchoalveolar lavage from controls (A),
and patients with active Behçet’s disease (BD) with pulmonary manifestations (B). The black histograms indicate fluorescence
intensity of control antibodies. Data are representative of 10 normal controls and eight active BD. Bcl-2 was expressed in CD3+
BAL-T lymphocytes at a higher intensity.
FIG.  2.  Results  of  double  staining  experiments  on  the
lymphocytes of representative bronchoalveolar lavage from
patients with active Behçet’s disease with pulmonary mani-
festations. Freshly isolated lymphocytes were stained with
FITC-conjugated anti-human CD3 monoclonal antibody. Fol-
lowing this step cells were permeabilized and then stained
with biotinylated polyclonal rabbit IgG anti-human Bcl-2, as
described  in  Patients  and  Methods.  As  control  for  the
expression of Bcl-2, cells were incubated with biotinylated
rabbit IgG and then with PE-conjugated streptavidin.
FIG. 3. The expression of Bcl-2 mRNA in peripheral blood,
bronchoalveolar lavage (BAL) and cerebrospinal fluid (CSF),
cells from patients with active Behçet’s disease (BD). Seven
micrograms of total RNA were blotted onto nylon membrane
and hybridized sequentially with Bcl-2 and GAPDH probes.
The dots represent the ratios of densitometric reading of Bcl-
2 and GAPDH expression. Each dot represents one patient.
Mean values are indicated by a line.Bcl-2mRNA expression
The increased expression of Bcl-2 in active BD at the
inflammatory sites could be demonstrated at the RNA
level. Bcl-2 mRNA expression was studied in active BD
in  12  PBMC,  six  BAL  and  five  CSF  samples. As  a
control, we used 10 PBMC and six BAL from healthy
controls and five CSF from patients with NIND. The
expression of Bcl-2 mRNA in PBMC from active BD
was increased compared to healthy controls. BAL and
CSF  from  active  BD  exhibited  an  increase  in  the
expression  of  Bcl-2  mRNA  compared  to  BAL  from
controls and CSF from patients with NIND (Fig. 3).
Bcl-2 expression after HSV-1 stimulation
The expression of Bcl-2 proto-oncogene was quanti-
fied in peripheral blood T cells after HSV-1 stimulation
(Table 3) in active BD, compared to NIND and healthy
controls. In healthy controls and patients with NIND,
Bcl-2  expression  exhibited  a  drastic  increase  after
HSV-1  stimulation  (P<0.001).  In  active  BD,  Bcl-2
expression increased slightly, but was not significantly
different from unstimulated HSV-1 T cells.
Discussion
Our findings indicate that Bcl-2 is overexpressed in
patients with active BD, both in PBMC and inflamma-
tory sites: BAL and CSF. This conclusion is based on
results  obtained  using  flow  cytometry  and  nucleic
acid hybridization. An increased expression of Bcl-2
has been previously demonstrated in active BD,4 and
in  SLE.17 The  mRNA  level  expression  of  apoptosis-
related gene product did not differ between SLE cells
and  normal  donor  cells.  Expression  of  Fas/APO-1
protein  was  increased  in  freshly  isolated  SLE  T
lymphocytes compared with normal donor T lympho-
cytes, whereas Bcl-2 protein was up-regulated after a
3-day culture period.18 Dysregulation of the apoptosis
system  in  RA  is  controversial.19 Increased  Bcl-2
expression,  and  in  general  programmed  cell  death
dysregulation, seemed to lead to autoimmune disease
and/or viral processes.
Some autoimmune mechanisms are involved in the
etiopathogenesis of BD,1 although there are disagree-
ments as to whether BD should be classified as an
autoimmune disease.20 The main immunological find-
ing in autoimmune disease is T cell hypofunction.21 BD
is essentially characterized by T cell hyperactivity.22
Taking  into  account  flow  cytometry  results  and
nucleic acid hybridization, we can conclude that there
is  a  certain  similarity  between  BD  and  SLE  in  the
apoptosis  defect,  characterized  by  increased  Bcl-2
expression.
A  possible  explanation  for  the  increased  Bcl-2
expression in the peripheral blood and inflammatory
sites in BD, was the increased production of IL-2,23
because  IL-2  has  been  shown  to  increase  Bcl-2
expression in active T cells.24 On the other hand, IL-10
has demonstrated to modulate the expression of Bcl-2
in  leukaemia  cells.25 IL-10  is  highly  produced  by
PBMC3 and plasma26 from patients with BD.  Therefore,
we studied the roles of IL-2 and IL-10 in the regulation
of  Bcl-2  expression  by  culturing  lymphocytes  with
exogenous IL-2, IL-10 or neutralizing anti-IL-10mAb.
Our  in  vitro data suggest  that IL-2 cytokine is  not
responsible for the increased expression of Bcl-2 in BD
inflammatory sites and peripheral blood lymphocytes.
However, IL-10 is able to increase in vitro expression
of  Bcl-2,  in  peripheral  blood  lymphocytes  and  in
inflammatory  lymphocytes. This  increase was  abro-
gated when lymphocytes were incubated with anti-IL-
10.
In patients with SLE, a prominent role for IL-10 in the
induction of apoptosis was observed,27 as neutralizing
anti-IL-10mAb markedly reduced cell death in active
SLE patients by 50%.27 Using Western blotting, it has
been demonstrated that exposure of IL-10 to T cells,
enhanced the  expression  of  Bcl-2,  inhibiting T  cell
apoptosis,  and  this  is  associated  with  a  normal
proliferative function.28
In  patients  suffering  from  viral  infection,  the
induction of apoptosis may result in virus clearance. In
contrast the inhibition of apoptosis may result in virus
cell  transformation and viral persistence. Epidemio-
logical  data  favour  an  infectious  cause,  and T  cell
hypersensitivity  for  BD:  Streptococcus  sanguis,29
parvovirus B19,30 and bacterial superantigens,31 have
been associated with BD. Antibodies to herpes simplex
virus 1 (HSV-1), were found to be increased in patients
with active BD.32,33 In a limited number of patients
with  BD,  a  HSV-1–DNA  fragment  was  found  in
peripheral blood lymphocytes by  polymerase chain
reaction (PCR). HSV DNA was found in biopsy samples
taken from genital ulcers by applying PCR, and the
289-bp protein of HSV DNA was also detected in these
lesions, but not in controls.33,34
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Table  3.  Bcl-2  expression  as  mean  fluorescence  intensity
(MFI) in peripheral blood T lymphocytes (PBL) after HSV-1
stimulation, in healthy controls (n = 10), patients with NIND
(n = 7) and patients with active BD (n = 12). Lymphocytes
were cultured in the presence of UV-inactivated HSV-1 in an
incubator with 5% CO2 for 6 days. On the day of testing cells
were washed and resuspended in RPMI 1640 medium
Sample Mean fluorescence
intensity ± S.D.
Before HSV-1
stimulation
After HSV-1
stimulation
Healthy Controls 53 ± 12 84 ± 6*
NIND 42 ± 16 82 ± 10*
Active BD 82 ± 9.5 97 ± 22
*P<0.001 compared to non-HSV-1-stimulated cells.The in vivo antigenic stimulation in active BD is
responsible for : (i) the activation of T lymphocytes
which  is  characterized  by  a  divergent  cytokine
production profile of mixed Th1/Th2 cell types;35 (ii)
the switch of na¨ õ ve T cells to memory lymphocytes;22
and (iii) the alteration of the inflammatory sites, with
destruction of the host tissues. All these factors might
account for the mechanisms of cell death observed in
our patients, which were characterized by increased
soluble CD95/APO-1,4 and increased expression of Bcl-
2 in the peripheral circulation and in the inflammatory
sites. Our results with regard to the lack of equilibrium
in  apoptosis  mechanisms  in  BD,  was  corroborated
with the insufficient expression of Fas on activated
CD4+ cells in BD.36 CD4+ T cells from patients with
active  BD,  were  characterized  to  mediate  specific
cytotoxicity against HSV-1.13
Our  data  confirmed  that  HSV-1  increased  Bcl-2
expression  in  active  BD,  undergoing  apoptosis  in
response to a variety of different agents. The question
is, whether Bcl-2 is able to interfere with Fas-induced
apoptotic cell death? Data indicate that Bcl-2 is capable
of inhibiting both the perforin/granzyme B- and Fas-
induced apoptotic cell death.37 Confirmation should
be established in the BD context.
Based on these data, we conclude that the specific
programmed cell death in BD might be explained, at
least in part, by the increased in vivoactivated levels of
lymphocytes in peripheral blood and in inflammatory
sites. The increased Bcl-2 protein expression in active
BD  are  non-specific  for  the  disease,  and  may  be
explained at least in  part by  the increased in vivo
activation  levels,  or  autoimmune  vasculitides  com-
bined  with  in  vivo induction  by  aetiopathological
agent(s).  These findings4,5,36 seem to play an important
role in the chronic inflammation in BD.
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